Tag: Malaysian Genomics Resource Centre Berhad

Malaysian Genomics Grows Presence in Thailand

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce today a series of collaborations to grow its customer base in Thailand as well as exploring opportunities for research and development (R&D) of new products and services.

Ms. Songsuda Panich, Founder of Marine Group; Encik Sasha Nordin, Chief Executive Officer of Malaysian Genomics; Mr. Choy Hong Yang, Director of Salus Holdings [L-R]

The Group signed a supply and collaboration agreement with Acquest Healthcare Stem Cell Research and Development Co. Ltd. to produce CAR T-cells for supply to Acquest’s customers. Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand. It operates a state-of-the-art clinical laboratory and also the largest privately-owned specialty human cell culturing facility in the country.

The Group also signed a supply and collaboration agreement with Salus Holdings Co. Ltd. (“Salus”) to supply biopharmaceutical and genomics products and services to Salus’ customers. Salus is a specialist in wellness and health screening using science and technology for early disease detection and managing programmes for lifestyle intervention based in Bangkok, Thailand.

Finally, the Group signed a Letter of Intent with Marine Group Co. Ltd. and Salus on collaborative research in the use of genetic screening tests and formulated cosmetic products containing certain cell therapy ingredients on the regeneration of skin and hair of patients. Marine Group is an aesthetic and wellness specialist with a network of over 42 centres under the brands Slim Up(TM), Skin Doctors(TM), and Biocell(TM).

The signing ceremony was attended by His Excellency Dato’ Jojie Samuel, Ambassador of Malaysia to Thailand and Encik Mohamed Hafiz Md Shariff, Trade Commissioner of MATRADE Bangkok.

Chief Executive Officer of Malaysian Genomics, Encik Sasha Nordin, said, “We are looking forward to a fruitful relationship with our Thai partners, Salus and Acquest. These collaborations are part of our strategy of growing our customer base and increasing our presence overseas through working with business partners who have an established presence in their respective market segments.”

Dr. Roland Neff, CEO of Acquest, said, “This collaboration is the first step as both parties explore the possibilities of conducting joint R&D that can result in new products and services that can be commercialised. We have a state-of-the-art clinical laboratory in Bangkok and also the largest privately-owned specialty human cell culturing facility in the country.”

Mr. Choy Hong Yang, Director of Salus, said, “At Salus, we use science and technology to provide services on disease detection, prevention and life-span improvement. This collaboration with Malaysian Genomics will enable us to leverage on their genetics knowledge and expertise to offer more products and services while the strategic cooperation is in keeping with our core value of joint innovation to offer new technologies to our customers.”

Ms. Songsuda Panich, Founder of Marine Group, said, “Skin Doctor, Slim Up and BioCell centres are always striving to provide the latest in skin and aesthetic science and technology for our customers. We look forward to collaborating with Malaysian Genomics and with Salus Healthcare on research and development involving cell regeneration products.”

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

Parties agree to collaborate on research in genetics, regenerative and alternative medicine

Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.

Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min

Under the LOI, MGRC, which owns a high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, as well as Genotec, which specializes in biomedical treatments using stem cells, will assist in strengthening the teaching and research activities of the undergraduate programme at UMS’ Faculty of Science and Natural Resources.

This cooperation will enable the exchange of research resources and ideas to enhance the quality of research at UMS, as well as create opportunities for students from the Faculty of Science and Natural Resources to serve their internship period at MGRC or Genotec.

Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, “We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study. This is also in support of the National Biotechnology Policy 2.0 launched recently focusing on agriculture and food security, healthcare and wellbeing, as well as industrial and the circular economy.”

The Dean of the Faculty of Science and Natural Resources, UMS, Professor Dr. Jualang Azlan Gansau said, “UMS is actively engaging in research as well as teaching activities and the involvement of industry is crucial in ensuring the relevance of such activities conducted at the University.”

The signing of the LOI followed UMS’ visit to MGRC’s Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Malaysian Genomics Reports RM28.36 Million Full-Year Revenue

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, reported revenue of RM6.33 million for the fourth quarter ended 30 June 2022 (4Q 2022) compared with the loss of RM0.07 million in the corresponding quarter of the previous financial year (4Q 2021) on higher contribution from the biopharmaceutical business and continued organic growth of the genetic testing business.

Sasha Nordin, Chief Executive Officer of Malaysian Genomics

The Group recorded a profit before tax (PBT) of RM2.97 million for the quarter under review compared with a loss before tax (LBT) of RM2.11 million in 4Q 2021 due to higher profit margin from the biopharmaceutical business as well as efficient cost monitoring.

For the financial year ended 30 June 2022 (FY2022), Malaysian Genomics registered revenue of RM28.36 million, which is an increase of RM26.58 million compared with RM1.78 million reported in the corresponding period of the previous financial year (FY2021) from growth of the biopharmaceutical business comprising of immunotherapy and cell therapies as well as COVID-19-related products and services.

The Group recorded PBT of RM6.18 million for FY2022 compared with LBT of RM4.29 million in FY2021 mainly due to higher revenue as a result of higher margin as well as cost efficiencies.

Earnings per share for 4Q 2022 stood at 3.25 sen compared with the loss per share of 1.94 sen in the corresponding quarter of the previous financial year.

En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, “We continue to see improvement in the Group’s financial performance, and this is attributable to the introduction of biopharmaceutical services as well as our aggressive push to market genetic testing services. Towards the tail-end of the quarter under review, we acquired a 51% stake in kidney dialysis operator Aquahealth Sdn Bhd in which we intend to introduce a holistic approach to kidney healthcare through our suite of products and services. We also have plans to open more such centres across Malaysia given the projected increase in the number of kidney patients.”

“We are also expanding in Southeast Asia and the Middle East with a series of agreements that we recently inked in which we collaborate with local partners to promote, market and distribute our biopharmaceutical and genetic testing services.”

About Malaysian Genomics Resource Centre Berhad

Malaysian Genomics Resource Centre Berhad (“Malaysian Genomics” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients. For more information, visit www.mgrc.com.my.

Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company.

Noor Azri Bin Dato’ Sri Noor Azerai, Executive Director of Malaysian Genomics, and H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group [L-R]

Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private equity, real estate and industrial investments.

As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products. Ajlan will also identify commercial research and development (R&D) opportunities for genome sequencing and analysis in the Middle East and North Africa (MENA) region for areas such as agriculture, aquaculture, plantations, healthcare and industrial biotechnology.

Malaysian Genomics on its part will analyse samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects through Ajlan.

Noor Azri Bin Dato’ Sri Noor Azerai, Executive Director of Malaysian Genomics, said, “This is a really good opportunity for us to explore the MENA market for our products and services, especially in the area of R&D where we see a lot of growth especially in agriculture and aquaculture due to climate change impact and the health diagnosis for distinct population groups.”

H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group, said, “We look forward to working with Malaysian Genomics to bring its biopharmaceutical and genetic services and products to Saudi Arabia, which is a good launchpad to the MENA region. This MoU is just the beginning as we explore how we can work closely together in the coming months.”

About Malaysian Genomics Resource Centre Berhad
Malaysian Genomics Resource Centre Berhad (“Malaysian Genomics” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients. For more information, visit www.mgrc.com.my.

Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU

Parties to look for collaborations in practice-based education, research and knowledge exchange and R&D

Malaysian Genomics Resource Centre Berhad‘s (Bursa: MGRC, 0155) wholly-owned subsidiary, MGRC Therapeutics Sdn. Bhd. signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.

En. Azri Azerai, Executive Director of Malaysian Genomics
Datin Dr Maya, Chief Executive Officer of MAHSA Health

Malaysian Genomics is the first company in Malaysia to pioneer genomics and genetic screening in Malaysia for over 17 years. Since then, Malaysian Genomics has expanded its offerings in other important areas in the healthcare and wellness that include cancer immunotherapy, cell manufacturing services and kidney dialysis. Malaysian Genomics continues to strive to provide the latest in precautionary, preventive and curative healthcare services for its local and worldwide customers.

MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of Companies, which is determined to be a revolutionary leader in healthcare. Since its inception in 2017, MAHSA Health has been striving to be in the forefront of primary healthcare, focusing on family health and wellness.

Encik Azri Azerai, Executive Directorof Malaysian Genomics said, “We look forward to sharing our experience in genomics, bioinformatics, and biopharmaceuticals with MAHSA Health via this collaboration. By providing industry inputs and insights to MAHSA, we hope to benefit students at MAHSA with the tremendous promise that various healthcare sciences have to offer for all.”

“Through this collaboration we also hope to identify opportunities to improve the delivery of integrated, holistic primary healthcare services, including genetic screening services to improve the lives of individuals in the long run.”

Datin Dr Maya, CEO of MAHSA Health, with her double expertise in health and wellness services, and education industry, said, “Passion is the greatest asset we each have. The main idea of MAHSA Health is to improve the quality of life in providing health care and wellness services to our community. We are a team-based healthcare that provides comprehensive medical care to patients with the goal of obtaining maximized health outcomes.”

“Through this collaboration, we foresee opportunities and collaborative efforts in many areas, both in health care and education industry in providing an ecosystem of teaching, training, and producing services to the country nationwide.”

The MoU is a framework through which MGRC Therapeutics and MAHSA Health can explore opportunities for health and wellness-related services; create opportunities for students’ clinical placement, internship and employment; identify opportunities for conducting collaborative research and development (R&D); and create opportunities in training, seminars and conferences.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Malaysian Genomics Appoints New Chairman

  • Former MOH Secretary General Dato’ Seri Dr Chen Chaw Min takes over effective 15 July 2022

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Company has appointed Dato’ Seri Dr Chen Chaw Min as the Independent Non-Executive Chairman of the Board of Directors.

Dato’ Seri Dr Chen Chaw Min, Independent Non-Executive Chairman of Malaysian Genomics
Dato’ Alvin Joseph, Executive Director of Malaysian Genomics

The appointment is effective 15 July 2022, following the resignation of Tan Sri Ahmad bin Mohd Don on 12 July 2022.

Dato’ Seri Dr Chen, who was appointed to the Board on 3 August 2021, was with the Malaysian civil service from 1988 until his retirement in February 2021. He was the Secretary-General of the Ministry of Health (MOH) from July 2015 until his retirement and has also served in various capacities in the Ministry of Finance (MOF) from 1990 until 2014.

Dato’ Seri Dr. Chen said, “I feel privileged to take on this role at such an exciting time for Malaysian Genomics. The Group is currently expanding downstream to healthcare services and pioneering holistic care which will benefit many for the years to come, I hope that my experience in both MOH and MOF will be able to add knowledge and insights to support the Company’s growth.”

Dato’ Alvin Joseph, Executive Director of Malaysian Genomics said, “We welcome Dato’ Seri Chen to the Board of Malaysian Genomics as Chairman of the Board and look forward to working with him in ensuring proper governance in our business operations. His extensive experience in the civil service and in particular in MOH will be invaluable to us.”

“We would like to extend our thanks to Tan Sri Ahmad bin Mohd Don for his invaluable contributions and guidance to the Board in executing their duties. We wish him all the best in his future endeavours.”

Dato’ Seri Dr Chen obtained a doctorate in finance from Universiti Putra Malaysia in 2005. He received an MBA (Finance) from University of Illinois in 1997 and a Bachelor in Surveying from University of Technology, Malaysia, in 1985.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia

Group to collaborate with United Doctors Hospital for genetic screening tests and cell therapies

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that it has entered into a strategic partnership with United Doctors Hospital (UDH) for collaboration in genomics and cell therapies.

Azri Azerai, Executive Director of Malaysian Genomics

UDH, located in Jeddah, Saudi Arabia, is accredited by the Saudi Central Board for Accreditation of Healthcare Institutions. UDH has also won numerous awards for social responsibility, including the King Khalid Award for Social Responsibility in 2018, and is certified with the SA8000, the world’s leading social certification programme, by Social Accountability International (formerly known as Social Accountability Accreditation Services), a United States-based charitable organisation, in 2016.

Under the partnership, which is valid for three years, Malaysian Genomics and UDH will take the necessary steps to encourage and promote cooperation in the sales and marketing of genetic screening tests and cell therapy products; collaboration in research and development (R&D), and other areas of cooperation in the genomics and cell therapies to be mutually decided by both parties.

Encik Azri Azerai, Executive Director of Malaysian Genomics, said, “This strategic partnership with UDH enables us to expand the geographical reach of our products and services beyond Malaysia to the Middle East and North Africa region. It will also enable us to collaborate on R&D with various domain specialists to enhance our suite of genetic screening tests and cell therapies.”

Dr. Hefny Moustafa Hefny, Medical Doctor at UDH, said, “Among the areas being explored by Malaysian Genomics and UDH are opportunities to develop genetic screening tests for hereditary conditions and diseases that are prevalent in the Middle East or Northern Africa, which may be different from other parts of the world.”

Malaysian Genomics is actively expanding its business-to-consumer channels as part of the Group’s growth strategy. The Group recently acquired a 51% stake in kidney dialysis operator Aquahealth Sdn Bhd to offer personalised kidney care that also involves nutrition management, lifestyle changes, and genetic testing. It is also collaborating with AirAsia’s Asean Super App online shopping platform and Speedoc to provide genetic screening services.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Malaysian Genomics Proposes Private Placement

  • Group to use proceeds for future viable investment and purchase of equipment

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is proposing to undertake a private placement of up to 10% of its total number of issued shares or up to 12.42 million new placement shares at an issue price to be determined for third-party investors that will be identified later.

Azri Azerai, Executive Director of Malaysian Genomics Resource Centre Berhad

Shareholders had approved in the AGM convened on 30 November 2021 for the Group to issue and allot new shares at any time and at such price as the Board of Directors deemed fit provided the number of new shares does not exceed 10% of the total number of issued shares. The new placement shares will rank equally in all respects with existing Malaysian Genomics shares except they will not be entitled to any dividends, rights, allotments and any other forms of distribution should the entitlement date precede the relevant date of allotment and issuance of the new placement shares.

Encik Azri Azerai, Executive Director of Malaysian Genomics, said, “We are proposing the private placement to raise funds mainly for the Group’s future investments of which we are still exploring options and a part of the proceeds will be allocated for the purchase of equipment including IT hardware, biological safety cabinet and extraction automation for our existing and future businesses.”

“The reopening of the economy presents opportunities in the private healthcare segment and the fresh funds raised will enable us to be able to take advantage of the possibilities. We diversified into the biopharmaceutical business in 2020 and have since been pushing to open channels for our cell therapies and genetic tests through a series of agreements that gives us a wider market reach. We also bought a 51% stake in a kidney dialysis operator, Aquahealth Sdn Bhd, to offer holistic kidney care.”

UOB Kay Hian Securities (M) Sdn Bhd is the adviser and placement agent for the proposed private placement.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Malaysian Genomics to Offer First-Ever Sports-Based Tests Specific to Southeast Asian Genetic Profiles

  • The Group is collaborating with Rinani Genotec to develop and offer genetic screening tests catering to athletes and those with active lifestyles

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that the Group’s wholly-owned subsidiary, MGRC Therapeutics Sdn Bhd (MGRCT), is collaborating with Rinani Genotec Sdn Bhd (Genotec) to offer sports-based genetic tests.

Genotec, a biomedical technology firm focusing on stem cell treatment and genetic testing, now offers a direct-to-consumer sports and fitness DNA test which enables individuals to better understand their genetic profile in sports and fitness-related areas. The test result includes categories such as energy metabolism and utilisation, muscle performance, response to cardiovascular training, weight management, nutrient metabolism, bone and joint health, and mental ability and performance. The information can then be integrated by individuals into their lifestyle in order to improve their daily sport and fitness performance.

The collaboration will see both parties consult and collaborate on sports-based genetic profile testing and the marketing of these services. In addition, Genotec will also work closely with MGRCT on the marketing of Malaysian Genomics’ full range of Dtect genetic screening tests.

Dato’ Alvin Joseph, Executive Director of MGRC, said, “This collaboration is another important step towards realising our vision of becoming a premier integrated life sciences company. By partnering with experts in sports science, we have now pioneered a genetic screening profile specifically designed for professional and amateur athletes, and everyday fitness enthusiasts. The science of genetics has a long history in professional sports and through this new profile we can support sportspeople in their pursuit of peak performance.”

Mr. Julian Koay, Genotec’s Director of Business Development, said, “With Malaysian Genomics’ experience in genetics, what we have developed can be a game-changer for athletes and sports talents. We will use this new sports genetic profile to personalise fitness, sports and recovery regimes of sportspeople, to improve their performance.”

Founders of Genotec, Julian Koay and Watson Chung, are the first certified DNA-based trainers in Malaysia, offering a unique programme combining knowledge of individuals’ genetic profiles with a fitness or training regime that enhances the effectiveness of the fitness or training programmes.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Malaysian Genomics Resource Centre to Offer Pioneering Holistic Renal Care via New Venture

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is acquiring a 51% stake in Aquahealth Sdn Bhd, a kidney dialysis operator, from Rinani Renal Berhad.

En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics

Aquahealth is establishing a kidney dialysis centre in Gombak, Selangor, with the license to operate the centre owned by the Malaysia International Islamic Chamber of Commerce. With the acquisition of the stake, Malaysian Genomics, through its wholly-owned subsidiary, MGRC Healthcare Sdn Bhd, will now become the operator of the dialysis centre.

En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, “This will be the first of many centres across the country that will be driven by a personalised kidney care model integrating dialysis with nutrition management, lifestyle changes, and even genetic testing of patients and their immediate family members. This pioneering approach will focus on bringing innovations in service delivery to improve the lives of patients with chronic kidney disease.”

“Expanding downstream to healthcare services, through our subsidiary MGRC Healthcare, is an important step in Malaysian Genomics’ growth as a diversified specialist healthcare group. The acquisition of the Aquahealth stake is part of our Group’s strategy to secure a diverse portfolio of earnings accretive assets across Southeast Asia that will, in turn, leverage and benefit from our genomics and biopharmaceutical knowledge and experience developed over the past 18 years.”

According to the Ministry of Health’s Management of Chronic Kidney Disease report, the number of Malaysians with kidney disease is projected to increase significantly in the future mainly due to the prevalence of diabetes, hypertension and an aging population[1]. At 13.2% per year, Malaysia has the second highest annual growth rate of chronic kidney disease in the world[2].

Dato’ Dr. Suhaini Kadiman, Chairman of Malaysia International Islamic Chamber of Commerce and Director of Clinical Research at Institute Jantung Negara added, “Thousands of kidney patients are on waiting lists for dialysis treatment and new centres are urgently needed. We welcome MGRC Healthcare’s interest to collaborate with us to operate the centre in Gombak, and we look forward to the innovations they will contribute to improve the lives of kidney dialysis patients.”

Recently, Minister of Health YB Tuan Khairy Jamaluddin noted that there were over 40,000 kidney patients in Malaysia, with over 8,000 new patients diagnosed annually since 2018[3].

[1] https://tinyurl.com/42jexjsk
[2] https://tinyurl.com/2cmkmzkz
[3] https://tinyurl.com/mr3mkfmk

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/